Literature DB >> 31332070

Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility.

L Silvia Munoz-Price1, Allison E Reeme2, Blake W Buchan3, Roberta T Mettus4, Mustapha M Mustapha4,5, Daria Van Tyne4,5, Ryan K Shields4,5, Yohei Doi6,5,7,8.   

Abstract

We report patient-to-patient transmission of Enterobacter hormaechei isolates with reduced susceptibility to ceftazidime-avibactam due to production of KPC-40, a variant of KPC-3 with a two-amino-acid insertion in the Ω-loop region (L167_E168dup). The index patient had received a prolonged course of ceftazidime-avibactam therapy, whereas the second patient had not received the agent and still became colonized with the KPC-40-producing strain. The complex dynamics of KPC (Klebsiella pneumoniae carbapenemase) described here highlight several key diagnostic and therapeutic considerations.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Enterobacter cloacae complex; avibactam; omega loop

Year:  2019        PMID： 31332070      PMCID： PMC6761506          DOI： 10.1128/AAC.00955-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.

Authors:  Krisztina M Papp-Wallace; Magdalena Taracila; John M Hornick; Andrea M Hujer; Kristine M Hujer; Anne M Distler; Andrea Endimiani; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

2.  Use of a cohorting-unit and systematic surveillance cultures to control a Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae outbreak.

Authors:  Allison E Reeme; Sarah L Bowler; Blake W Buchan; Mary Beth Graham; Elizabeth Behrens; Siddhartha Singh; Johnny C Hong; Jennifer Arvan; Joshua W Hyke; Louis Palen; Sabrina Savage; Heather Seliger; Susan Huerta; Nathan A Ledeboer; Shireen Kotay; Amy J Mathers; Vaughn S Cooper; Mustapha Munir Mustapha; Roberta T Mettus; Yohei Doi; L Silvia Munoz-Price
Journal:  Infect Control Hosp Epidemiol       Date:  2019-05-14       Impact factor: 3.254

3.  Genomic Characterization of Two KPC-Producing Klebsiella Isolates Collected in 1997 in New York City.

Authors:  Brandon Eilertson; Liang Chen; Kalyan D Chavda; Barry N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.

Authors:  Ryan K Shields; Liang Chen; Shaoji Cheng; Kalyan D Chavda; Ellen G Press; Avin Snyder; Ruchi Pandey; Yohei Doi; Barry N Kreiswirth; M Hong Nguyen; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

5.  Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type beta-lactamase by use of a boronic acid compound.

Authors:  Yohei Doi; Brian A Potoski; Jennifer M Adams-Haduch; Hanna E Sidjabat; Anthony W Pasculle; David L Paterson
Journal:  J Clin Microbiol       Date:  2008-10-15       Impact factor: 5.948

Review 6.  Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.

Authors:  L Silvia Munoz-Price; Laurent Poirel; Robert A Bonomo; Mitchell J Schwaber; George L Daikos; Martin Cormican; Giuseppe Cornaglia; Javier Garau; Marek Gniadkowski; Mary K Hayden; Karthikeyan Kumarasamy; David M Livermore; Juan J Maya; Patrice Nordmann; Jean B Patel; David L Paterson; Johann Pitout; Maria Virginia Villegas; Hui Wang; Neil Woodford; John P Quinn
Journal:  Lancet Infect Dis       Date:  2013-09       Impact factor: 25.071

7.  Microbiological features of KPC-producing Enterobacter isolates identified in a U.S. hospital system.

Authors:  Chulsoo Ahn; Alveena Syed; Fupin Hu; Jessica A O'Hara; Jesabel I Rivera; Yohei Doi
Journal:  Diagn Microbiol Infect Dis       Date:  2014-06-23       Impact factor: 2.803

8.  Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.

Authors:  David van Duin; Judith J Lok; Michelle Earley; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Vance G Fowler; David L Paterson; Robert A Bonomo; Scott Evans
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

9.  Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads.

Authors:  Ryan R Wick; Louise M Judd; Claire L Gorrie; Kathryn E Holt
Journal:  PLoS Comput Biol       Date:  2017-06-08       Impact factor: 4.475

10.  Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.

Authors:  Melissa D Barnes; Marisa L Winkler; Magdalena A Taracila; Malcolm G Page; Eric Desarbre; Barry N Kreiswirth; Ryan K Shields; Minh-Hong Nguyen; Cornelius Clancy; Brad Spellberg; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  MBio       Date:  2017-10-31       Impact factor: 7.867
View more
  7 in total

1.  KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.

Authors:  Vincenzo Di Pilato; Noemi Aiezza; Valentina Viaggi; Alberto Antonelli; Luigi Principe; Tommaso Giani; Francesco Luzzaro; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

2.  WCK 5222 (Cefepime/Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-lactamase producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

Review 3.  Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.

Authors:  Claire Amaris Hobson; Gautier Pierrat; Olivier Tenaillon; Stéphane Bonacorsi; Béatrice Bercot; Ella Jaouen; Hervé Jacquier; André Birgy
Journal:  Antimicrob Agents Chemother       Date:  2022-08-18       Impact factor: 5.938

4.  In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae.

Authors:  Jacqueline Findlay; Céline Rens; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2022-09-26       Impact factor: 5.938

5.  A Two Amino Acid Duplication, L167E168, in the Ω-Loop Drastically Decreases Carbapenemase Activity of KPC-53, a Natural Class A β-Lactamase.

Authors:  Alessandra Piccirilli; Sabrina Cherubini; Giuseppe Celenza; Gian Maria Rossolini; Fabrizia Brisdelli; Bernardetta Segatore; Luigi Principe; Francesco Luzzaro; Lilia Andriani; Gianfranco Amicosante; Mariagrazia Perilli
Journal:  Antimicrob Agents Chemother       Date:  2022-06-01       Impact factor: 5.938

6.  Modelling of the transmission dynamics of carbapenem-resistant Klebsiella pneumoniae in hospitals and design of control strategies.

Authors:  Suttikiat Changruenngam; Charin Modchang; Dominique J Bicout
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.996

7.  Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient.

Authors:  Paolo Gaibani; Linda Bussini; Stefano Amadesi; Michele Bartoletti; Federica Bovo; Tiziana Lazzarotto; Pierluigi Viale; Simone Ambretti
Journal:  Microorganisms       Date:  2022-04-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.